On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

  • Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies
  • The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers
  • Odyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts and allow interested investors to access information regarding the company
  • The website redesign follows on the company’s name change earlier this year to similarly improve the expression of its brand identity

Medical technology product developer Odyssey Health (OTC: ODYY) is advancing testing for a proprietary drug and device combination designed to deliver a novel solution for people experiencing a concussive brain injury, and the company recently introduced a redesigned website to help it better communicate its progress.

Odyssey Health has completed preclinical animal testing on its fully synthetic neurosteroid known currently as PRV-002 and is now beginning work with human clinical volunteers. In the animal testing, PRV-002 demonstrated the ability to alleviate symptoms related to concussions such as memory impairment, anxiety and motor/sensory difficulties. 

The redesign of the company website follows on Odyssey’s name change earlier this year to emphasize Odyssey’s brand focus on the health therapy industry and its mission to “create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions,” including PRV-002 and products to remove a throat obstruction in a choking person, to establish a standard of early detection for heart disease, and to treat the neuro-degenerative Niemann-Pick disease. 

“The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” CEO Michael Redmond stated Aug. 4 (https://ibn.fm/ATWbK).

The website’s address is www.OdysseyHealthInc.com. In addition, the company has updated its corporate presentation to better express the need for a concussive brain injury treatment as well as Odyssey’s efforts to lead the way. The new presentation can be found at https://ibn.fm/TooCZ.

The federal government’s Centers for Disease Control and Prevention (“CDC”) estimates that about 1.5 million people in the United States experience traumatic brain injuries (“TBIs”) each year (https://ibn.fm/Wb08R). The agency’s most recent data indicates that of these TBIs, about 223,135 were serious enough in 2019 to lead to hospitalizations and 64,362 resulted in death — effectively 611-plus TBI-related hospitalizations per day and 176 TBI-related deaths per day (https://ibn.fm/5ih3M).

The CDC reports that a large number of TBI deaths result from suicides, but the incidence of TBI-related injuries in child athletes, in particular, has drawn national attention to concerns about the long-term effects of head injuries and efforts to prevent or respond to them. 

Professional athletes, military personnel and elderly fall victims have also been recognized as a large segment of society that could benefit from effective treatment of concussion head injuries. 

Currently, the standard of care for concussions is rest, pain-relief medicine and anti-depressants. Such TBIs are generally initially reported as mild injuries (“MTBIs”) because of their minimal degree of impairment for normal activities, but the CDC’s reports note that long-term effects such as memory impairment have resulted in an estimated 5.3 million Americans living with a permanent TBI-related disability. 

Repeat concussions can lead to early dementia and a condition known as Chronic Traumatic Encephalopathy (“CTE”), but at the time no drug treatment for such injuries has been approved by the U.S. Food and Drug Administration (“FDA”). 

Odyssey Health’s product is an intranasal device that delivers the proprietary neurosteroid into the upper nasal cavity (but not into the esophagus or lungs), where it can be taken up into the brain, across the blood-brain barrier, to minimize the results of the injury. 

The company intends to build on its flagship product with eventual therapies for other brain injury and neuropsychiatric disorders ranging from serious depression to amyotrophic lateral sclerosis (known as ALS, or Lou Gehrig’s disease). 

In addition to its website, Odyssey provides updates on its activities through social media channels, such as Twitter (https://twitter.com/OdysseyHealth1), Facebook (https://www.facebook.com/odysseyhealthinc) and LinkedIn (www.linkedin.com/company/odysseyhealthinc/). YouTube: (https://www.youtube.com/channel/UCsS–v0od_fYIBu2tvqmj9Q )

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered